Nebenwirkungen · Tremfya
Tremfya 100 mg OnePress solution for injection in pre-filled pen Tremfya 100 mg PushPen solution for injection in pre-filled pen · Abschnitt 4.8 · PDF-Seite 72
HOS-137358 · Präparat HOS-098012
In the psoriasis clinical studies, through 1 year, the frequency of transaminase increases (ALT and AST) for the guselkumab q8w dose was similar to that observed for the guselkumab q8w dose in the psoriatic arthritis clinical studies. Through 5 years, the incidence of transaminase elevation did not increase by year of guselkumab treatment. Most transaminase increases were ≤ 3 x ULN.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-23T16:31:00Z · SHA-256 039a821487750437322e4aaaaa4a6ce804d9bf8a0433b6d64d8e85ad2e523477 · Passage 029422e814e35cbb83c7d7fcd686cc37c6026468de4f116196ccc2be48b8afe7 · Zeichen 5175–5560 im Abschnitt